EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers.

Cell Oncol (Dordr) · 2025 · PMC12528223 · PMID 40637801

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might be significantno p-value reported

Though our research mainly focuses on KRAS G12C and KRAS G12D cells, oncogenic mutations on KRAS gene show high heterogeneity, and consequently downstream signaling and drug response might be significant divergent due to structure difference of the mutation sites [ 55 , 56 ].

also in 2,457 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.